Search results for "030226 pharmacology & pharmacy"

showing 10 items of 317 documents

GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease non-transgenic rat model

2015

Background: GABAergic inhibitory action regulates learning/memory processes and contributes to neurotransmission (Gong et al., 2009). Existing evidence suggests GABAergic system is involved in pathophysiology of Alzheimer’s disease (AD) via inhibitory interneuron deficits (Verret et al., 2012) and decrease in functional GABAA receptors (Limon et al., 2012). In vitro, GABA and muscimol (GABAA receptor agonist) blocked neuronal death induced by Aβ in rat hippocampal and cortical neurons (Paula-Lima et al., 2005). Our concept: low doses of muscimol may prevent learning/memory deficits in intracerebroventricular (icv) streptozocin (STZ)-induced AD non-transgenic rat model. Methods. Wistar male …

Agonistmedicine.medical_specialtymedicine.drug_class02 engineering and technologyWater mazeNeurotransmissionHippocampal formationInhibitory postsynaptic potential030226 pharmacology & pharmacymemory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineMultidisciplinarybusiness.industryGABAA receptorstreptozocin021001 nanoscience & nanotechnologymuscimol3. Good healthEndocrinologynervous systemMuscimolchemistryAnesthesiaPoster PresentationGABAergic0210 nano-technologybusinessSpringerPlus
researchProduct

Micellar liquid chromatography determination of rivaroxaban in plasma and urine. Validation and theoretical aspects.

2019

A Micellar Chromatographic method to determine rivaroxaban in plasma and urine has been developed. The samples were dissolved in the mobile phase (SDS 0.05 M – 1-propanol 12.5%, phosphate buffered at pH 7) and 20 μL directly injected, avoiding the extraction and purification steps. Using a C18 column and running under isocratic mode at 1 mL/min, analyte was eluted without interference from the matrix in <6.0 min. The detection absorbance wavelength was set to 250 nm. The procedure was validated by Food and Drug Administration guidelines in terms of: system suitability, calibration range (0.05–5 mg/L), linearity, sensitivity, robustness, carry-over effect, specificity, accuracy (−11.1 to 4.2…

AnalyteClinical Biochemistrypartition equilibriumUrine030226 pharmacology & pharmacy01 natural sciencesBiochemistryAnalytical Chemistrymicellar chromatographyMatrix (chemical analysis)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRivaroxabanLimit of Detectiondirect injectionHumansMicellesvalidationChromatographyElutionanticoagulant010401 analytical chemistryExtraction (chemistry)biological fluidReproducibility of ResultsCell BiologyGeneral MedicinePhosphate0104 chemical scienceschemistryMicellar liquid chromatographyPartition equilibriumLinear ModelsChromatography LiquidJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways …

2018

A semi-physiological two compartment pharmacokinetic model with two active metabolites (primary (PM) and secondary metabolites (SM)) with saturable and non-saturable pre-systemic efflux transporter, intestinal and hepatic metabolism has been developed. The aim of this work is to explore in several scenarios which analyte (parent drug or any of the metabolites) is the most sensitive to changes in drug product performance (i.e. differences in in vivo dissolution) and to make recommendations based on the simulations outcome. A total of 128 scenarios (2 Biopharmaceutics Classification System (BCS) drug types, 2 levels of KM Pgp, in 4 metabolic scenarios at 2 dose levels in 4 quality levels of t…

AnalyteCmaxPharmaceutical ScienceAdministration Oral02 engineering and technologyEquivalence Trials as TopicPharmacologyBioequivalence030226 pharmacology & pharmacyModels Biological03 medical and health sciencesFirst pass effect0302 clinical medicinePharmacokineticsHumansComputer SimulationPharmacokineticsIntestinal MucosaBiotransformationChemistryMembrane Transport Proteins021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemNONMEMNonlinear DynamicsPharmaceutical PreparationsSolubilityTherapeutic EquivalencyResearch DesignArea Under CurveLinear Models0210 nano-technologyMonte Carlo MethodDrug metabolismEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Relationship between particle size and dissolution rate of bulk powders and sieving characterized fractions of two qualities of orthoboric acid

1996

Drug Dev. Ind. Pharm. ISI Document Delivery No.: VN279 Times Cited: 1 Cited Reference Count: 22 Tromelin, A Habillon, S Andres, C Pourcelot, Y Chaillot, B; International audience; We have carried out a study of the particle size distribution and aqueous dissolution rate of two commercially available qualities of orthoboric acid, labeled ''crystal'' (ABC) and ''powder'' (ABP). In a previous work, we have shown that the two commercial qualities of orthoboric acid chosen as model compound (''powder'' and ''crystal'') are related to the same crystal network in spite of their different names. However, these two qualities have very different size particle distributions, as previously determined b…

Analytical chemistryPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacyrelease03 medical and health sciences0302 clinical medicine[CHIM.ANAL]Chemical Sciences/Analytical chemistryDrug DiscoverymorphologySize fractionsDissolution testingdissolution rateDissolutionfractal geometryPharmacologyAqueous solutionChemistryOrganic Chemistryparticle size021001 nanoscience & nanotechnologyLaser light scattering[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistryCrystallography[SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacologyParticle-size distributionParticle size0210 nano-technology
researchProduct

The Effect of Methanolic Leaf Extract of Boerhavia diffusa Linn. (Nictaginaceae) on the Activities of Antidiabetic, Anti-inflammatory and Antioxidant…

2018

Diabetic therapeutic potentiality of methanol extract of stem leaves of Boerhavia diffusa was investigated following in-vivo study models in streptozotocin-induced diabetic rat. Methanol extract of stem leaves of Boerhavia diffusa exerted the glucose lowering effect an increase in serum insulin level on 28st day of postadministration. In addition to a higher expression of insulin receptor A. The extract treatment or glibenclamide for 28 days significantly (p<0.05) reduced HbA1c. Boerhavia diffusa L. or glibenclamide for 28 days show no damaging effect on red blood count and hemoglobin when compared to the control group.  Significant (p<0.05) increase in platelet count and white blood cell c…

AntioxidantBoerhaviabiologyTriglyceridemedicine.drug_classmedicine.medical_treatmentPharmacologybiology.organism_classificationAscorbic acid030226 pharmacology & pharmacyAnti-inflammatoryGlibenclamideLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesismedicineXanthine oxidasemedicine.drugJournal of Pharmaceutical Research International
researchProduct

Mucoadhesive Polymeric Films to Enhance Barbaloin Penetration Into Buccal Mucosa: a Novel Approach to Chemoprevention.

2018

Nowadays, chemoprevention by administering natural supplements is considered an attractive strategy to reverse, suppress, or prevent the evolution of premalignant oral lesions. In particular, Barbaloin exhibits anti-proliferative, anti-inflammatory, and anti-cancer properties, and it results useful in multi-therapy with classic chemotherapeutics. Therefore, in this work, mucoadhesive buccal films, as locoregional drug delivery system able to provide a targeted and efficient therapeutic delivery of Barbaloin, are proposed. Thus, Aloin extract-loaded Eudragit (R) RL100 or Eudragit (R) RS100-based buccal films were designed in order to obtain an easily self-administrable formulation capable of…

Barbaloinbuccal filmCell SurvivalPolymersSwineAcrylic ResinsPharmaceutical ScienceAloin02 engineering and technologyAquatic Science030226 pharmacology & pharmacyChemoprevention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsAdhesivesDrug DiscoveryMucoadhesionmedicineAnimalsHumansEcology Evolution Behavior and SystematicsCells Culturedchemistry.chemical_classificationAnthracenesEcologyDose-Response Relationship Drugex vivo permeationPlasticizerMouth MucosaAdministration BuccalGeneral MedicinePolymerBuccal administrationPenetration (firestop)021001 nanoscience & nanotechnologyDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptom0210 nano-technologyAgronomy and Crop SciencemucoadhesionBiomedical engineeringAAPS PharmSciTech
researchProduct

Innovative strategies to treat skin wounds with mangiferin: fabrication of transferosomes modified with glycols and mucin

2020

Aim: The moisturizing properties of glycerol, the penetration enhancing capability of propylene glycol and the bioadhesive properties of mucin were combined to improve the carrier capabilities of transfersomes and the efficacy of mangiferin in the treatment of skin lesions. Materials &amp; methods: Mangiferin was incorporated in transfersomes and glycoltransfersomes, which were also modified with mucin. The physico–chemical features were assessed, along with the efficacy against oxidative stress and skin wounds in vitro and in vivo. Results: Glycoltransfersomes promoted the deposition of mangiferin in epidermis and dermis, protected fibroblasts from oxidative stress and stimulated their pr…

BioadhesiveXanthonesBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyDevelopmentPharmacologymedicine.disease_cause030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDermisIn vivoGlycerolmedicineGeneral Materials ScienceMangiferinSkinGlicolsWound Healingintegumentary systemMucinMucins021001 nanoscience & nanotechnologySkin diseasesmedicine.anatomical_structurechemistryMalalties de la pell0210 nano-technologyWound healingOxidative stress
researchProduct

Effect of actively targeted copolymer coating on solid tumors eradication by gold nanorods-induced hyperthermia.

2020

Efforts in the field of anticancer therapy are increasingly focusing on the development of localized and selective treatments. Photothermal therapy (PTT) can lead to a spatially confined death of cancer cells, exploiting an increasing in temperature generated after UV-NIR irradiation of peculiar materials. Herein, a new actively targeted gold-based drug delivery system, named PHEA-LA-Fol-AuNRs/Iri, was explored for hyperthermia and chemotherapy colon cancer treatment. Gold nanorods were stabilized using a folate-derivative of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA-LA-PEG-FA) as coating agent and then loaded with the antineoplastic drug irinotecan (Iri). The efficacy of empty and i…

BiodistributionColorectal cancerPolymersPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health sciencesMice0302 clinical medicineIn vivoCell Line TumorNeoplasmsmedicineGold nanorodsHyperthermiaPhotothermal therapySolid tumorMagnetic resonance imaging folic acidAnimalsHyperthermiaTissue DistributionNanotubesChemistryCancerHyperthermia InducedPhotothermal therapyPhototherapy021001 nanoscience & nanotechnologymedicine.diseaseIrinotecanDrug deliveryCancer cellCancer researchGold0210 nano-technologymedicine.drugInternational journal of pharmaceutics
researchProduct

Effect of endothelial cell heterogeneity on nanoparticle uptake.

2020

Endothelial cells exhibit distinct properties in morphology and functions in different organs that can be exploited for nanomedicine targeting. In this work, endothelial cells from different organs, i.e. brain, lung, liver, and kidney, were exposed to plain, carboxylated, and amino-modified silica. As expected, different protein coronas were formed on the different nanoparticle types and these changed when foetal bovine serum (FBS) or human serum were used. Uptake efficiencies differed strongly in the different endothelia, confirming that the cells retained some of their organ-specific differences. However, all endothelia showed higher uptake for the amino-modified silica in FBS, but, inter…

Biodistributionmedia_common.quotation_subjectReceptor expressionEndothelial cellsBristol Heart InstitutePharmaceutical ScienceUptake02 engineering and technologyADHESIONBlood–brain barrier030226 pharmacology & pharmacySERUM03 medical and health sciencesDELIVERY0302 clinical medicineBIODISTRIBUTIONmedicineHumansBovine serum albuminInternalization/dk/atira/pure/core/keywords/heart_SRImedia_commonchemistry.chemical_classificationKidneyPROTEIN-CORONAbiologyChemistryBLOOD-BRAIN-BARRIEREndothelial CellsBiological Transportrespiratory system021001 nanoscience & nanotechnologyCell biologyEndothelial stem cellSURFACE-CHARGEmedicine.anatomical_structureSIZENanomedicineTransferrinProtein coronabiology.proteinINTERNALIZATIONNanoparticlesProtein CoronaHeterogeneityMEMBRANE0210 nano-technologyEndothelial cell targetingInternational journal of pharmaceutics
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] &gt;300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct